S&P/ASX 200 Index (ASX: XJO) shares closed 0.32% lower on Thursday at 8,709.4 points.
Two experts have highlighted a couple of ASX 200 shares suffering price weakness today — and why they're a buy-the-dip opportunity.
Let's check them out.
Image source: Getty Images
Experts say buy the dip on these ASX 200 shares
Domino's Pizza Enterprises (ASX: DMP)
The Domino's Pizza share price closed 0.7% lower at $18.45 on Thursday.
The ASX 200 retail share lost a quarter of its market value in one day earlier this month on news of the CEO's shock departure.
Domino's shares slumped 26% to a 52-week low of $14.80 as the market reacted to Mark van Dyck's plan to leave on 23 December.
He's less than a year into the job, having only taken over in November 2024 after Don Meij retired.
Domino's chair and largest shareholder, Jack Cowin, has stepped in to run the show while they search for a new CEO.
In a new note, Ord Minnett said:
This suggests to Ord Minnett that the turnaround job at the fast-food chain may be a much larger task than Van Dyck – and the market – expected, despite what appeared to be the CEO's apparent rapid progress in resetting the business, e.g. the closure of 205 loss-making stores in Japan and Europe.
It may well be that Cowin, who made his fortune with the Hungry Jack's franchise, did not see changes to the business being deep enough or implemented fast enough.
Nonetheless, it is a puzzling decision given Van Dyck appeared to be a 'captain's pick' by the chairman after his earlier consulting work with Domino's.
Ord Minnett has reworked its Domino's model in a "major way".
The broker said it all but discounts any network growth and expects same-store sales growth to slow.
The broker also forecasts no final dividend for FY25 and none in FY26.
Nonetheless, the broker has raised its rating from hold to buy given the attractive valuation of this ASX 200 share since its crash.
The broker said:
We have trimmed our FY25 EPS estimate by 0.6%, while our FY26 and FY27 forecasts fall by 1.1% and 5.9%, respectively, leading to a cut in target price to $28.00 from $31.00.
We have raised our recommendation to Buy from Hold given the very attractive value now on offer.
CSL Ltd (ASX: CSL)
The CSL share price closed 1.53% higher at $269.56 on Thursday.
CSL remains the largest ASX 200 healthcare share despite a 13% slide in its share price over the past 12 months.
CSL is an Australian biotech and the world's biggest blood collector. Its Seqirus division is one of the world's largest influenza vaccine companies. Its Behring division focuses on rare and serious diseases, and its Vifor division specialises in renal disease treatment.
CSL was in the news recently after President Donald Trump indicated he was considering a 200% tariff on pharmaceutical imports.
On The Bull this week, Dylan Evans from Catapult Wealth said this would likely have an impact on CSL's revenue.
But he still rates the ASX 200 share a buy.
Evans explained:
…CSL is trading on an attractive valuation against global peers, particularly for a company with a history of double-digit growth.
We see weakness as an opportunity to buy a high quality company at an attractive price.
There's a distinct possibility that any Trump tariff has less impact than expected, or is ultimately watered down, or simply disappears as part of another Trump backflip.
